Edition:
United States

OPKO Health Inc (OPK.OQ)

OPK.OQ on NASDAQ Stock Exchange Global Select Market

3.80USD
23 Feb 2018
Change (% chg)

$0.18 (+4.97%)
Prev Close
$3.62
Open
$3.66
Day's High
$3.83
Day's Low
$3.65
Volume
625,714
Avg. Vol
1,017,750
52-wk High
$8.69
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Opko Health qtrly loss per share $0.08‍​
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Opko Health Inc ::Opko Health reports 2017 third quarter highlights and financial results.Q3 revenue $263.5 million versus I/B/E/S view $319.4 million.Opko Health Inc qtrly loss per share $0.08‍​.  Full Article

OPKO Health submits premarket approval application with FDA for PSA test
Tuesday, 7 Nov 2017 08:00am EST 

Nov 7 (Reuters) - OPKO Health Inc :OPKO Health submits premarket approval application with FDA for a point-of-care PSA test with the Claros 1 platform.OPKO Health Inc - ‍filing contains clinical data from company's 864-patient total psa clinical study​.OPKO Health Inc - ‍OPKO expects to initiate clinical validation studies and to file a 510(k) application for a Claros 1 testosterone test in 2018​.OPKO Health - working to add additional tests for vitamin D, infectious diseases, cardiology, women's health, companion diagnostics to Claros 1 menu​.  Full Article

Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc
Thursday, 2 Nov 2017 08:05am EDT 

Nov 2 (Reuters) - Xenetic Biosciences :Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc.Xenetic Biosciences Inc - ‍Xenetic to receive one-time payment of $7.5 million and single digit royalty payments based upon net sales​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 10:19am EDT 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan
Thursday, 12 Oct 2017 08:00am EDT 

Oct 12 (Reuters) - Opko Health Inc :Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee® in Japan.Opko Health Inc - ‍Under terms of agreement, JT will make an upfront payment to Opko of $6 million.Opko Health says unit ‍eirgen Pharma entered into an exclusive agreement with Japan Tobacco for development and commercialization in Japan of Rayaldee​.Opko Health - As per agrement, co eligible to receive up to additional $31 million in development & regulatory milestones & $75 million in sales based milestones​.Opko Health Inc - JT will make​ another ‍$6 million payment to co upon initiation of Opko's planned phase 2 study of Rayaldee in U.S. dialysis patients.  Full Article

Opko Health CEO Phillip Frost​ buys 40,000 shares of co's common stock on Aug 16
Thursday, 17 Aug 2017 07:27am EDT 

Aug 17 (Reuters) - Opko Health Inc :Opko Health CEO Phillip Frost​ reports purchase of 40,000 shares of co's common stock on Aug 16 - SEC filing.  Full Article

Opko Health CEO Phillip Frost​ buys 25,000 shares of co's common stock on Aug 15
Wednesday, 16 Aug 2017 07:30am EDT 

Aug 16 (Reuters) - Opko Health Inc :Opko Health Inc <<>> CEO Phillip Frost​ reports purchase of 25,000 shares of co's common stock on Aug 15 - SEC filing.  Full Article

OPKO Health reports Q2 loss per share $0.04
Tuesday, 8 Aug 2017 04:15pm EDT 

Aug 9 (Reuters) - OPKO Health Inc -:OPKO Health reports second quarter 2017 business and financial results.Q2 revenue $314.2 million versus I/B/E/S view $322.6 million.OPKO Health Inc qtrly loss per share $0.04.  Full Article

Opko Health CEO Phillip Frost buys 50,000 shares of co's common stock on July 10
Tuesday, 11 Jul 2017 06:46am EDT 

July 11 (Reuters) - Opko Health Inc :Opko Health Inc CEO Phillip Frost reports purchase of 50,000 shares of co's common stock on July 10 - SEC filing.  Full Article

Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer
Monday, 26 Jun 2017 08:35am EDT 

June 26 (Reuters) - Xenetic Biosciences Inc :Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer.Xenetic Biosciences Inc- Patient dosing expected in Q3 2017.  Full Article

BRIEF-Opko Health qtrly loss per share $0.08‍​

* Opko Health reports 2017 third quarter highlights and financial results